The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 01, 2022

Filed:

Aug. 15, 2019
Applicant:

Merck Patent Gmbh, Darmstadt, DE;

Inventors:

Ilhan Celik, Zwingenberg, DE;

Eike Staub, Darmstadt, DE;

Miriam Urban, Leidersbach, DE;

Sabine Raab, Rosbach, DE;

Eileen Samy, Arlington, MA (US);

Andrew Bender, Reading, MA (US);

Georgianna Higginbotham, Tewksbury, MA (US);

Yin Wu, Andover, MA (US);

Daigen Xu, Westford, MA (US);

Assignee:

Merck Patent GmbH, Darmstadt, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12Q 3/00 (2006.01); A61P 17/02 (2006.01); A61P 11/00 (2006.01); G01N 33/543 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2848 (2013.01); A61K 39/395 (2013.01); A61P 11/00 (2018.01); A61P 17/02 (2018.01); C07K 16/2839 (2013.01); C12Q 3/00 (2013.01); G01N 33/54366 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting αv-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.


Find Patent Forward Citations

Loading…